64
d) Interest rate risk
Changes in interest rates change the fair value of assets and liabilities that accrue a fixed interest rate, as
well as the future flows of assets and liabilities referenced to a variable interest rate. However, it contemplates
the use of hedging operations with the aim of achieving a balance in the structure of the debt that allows the
cost of debt to be minimised over the multi-year horizon with reduced volatility in the income statement.
In this regard, on February 17, 2017, the Company proceeded to formalize a financial instrument derived
from the Interest Rate Swap (IRS), for an amount of 8,550,000 euros, whose term is between April 1, 2019
and April 1, 2026, linked to a mortgage loan for an amount of 11,400,000 euros contracted in 2017 on the
property located in the Calle José Abascal 41 in Madrid.
On May 23, 2024, the Company proceeded to formalize a financial instrument derived from the Interest Rate
Swap (IRS with sale of CAP), for an amount of 18,432,000 euros, whose term is between May 23, 2024 and
February 23, 2036, linked to a mortgage loan for an amount of 36,000,000 euros contracted in the 2023
financial year on the Sanitas Valdebebas Hospital which is currently under construction.
On May 23, 2024, the Company proceeded to formalize a financial instrument derived from the Interest Rate
Swap (IRS with sale of CAP), for an amount of €28,188,600, whose term is between June 30, 2024 and
September 30, 2035, linked to a mortgage loan for an amount of €33,000,000 contracted in 2022 on the
Meliá Innside Hotel Valdebebas which has completed its construction during 2024.
On July 25, 2024, the Company proceeded to formalize a financial instrument derived from an Interest Rate
Swap (IRS with sale of CAP), for an amount of €23,280,000 each, whose term is between July 26, 2024 and
October 26, 2037. linked to a mortgage loan for an amount of 24,000,000 euros contracted in the 2022
financial year on the property located at Calle Arapiles 14 in Madrid.
On August 5, 2024, the Company proceeded to formalize a financial instrument derived from the Interest
Rate Swap (IRS with sale of CAP), for an amount of €8,837,500 each, whose term is between July 26, 2024
and October 26, 2032. linked to a personal loan for an amount of 10,000,000 euros contracted in the 2022
financial year linked to the property located at Calle Arapiles 14 in Madrid.
e) Real estate business risks
Changes in the economic situation, both domestically and internationally, growth rates in employment and
employment rates, interest rates, tax legislation and consumer confidence have a significant impact on real
estate markets. Any unfavourable change in these or other economic, demographic or social variables in
Europe, and in Spain in particular, could result in a decrease in real estate activity in these countries. The
cyclical nature of the economy has been statistically proven, as well as the existence of both micro and
macroeconomic aspects that, directly or indirectly, affect the behaviour of the real estate market, and in
particular that of the rentals that make up the Company's main investment activity.
Other market risks to which the Company is exposed are:
• Regulatory risks: the Company is subject to compliance with the different applicable regulations
in force, both general and specific (legal, accounting, environmental, labour, tax, data protection
regulations, among others). Regulatory changes that occur in the future could have a positive or
negative effect on the Company.
• Tourism Risk: a significant part of the Company's assets (mainly Hotels) are linked to the tourism
sector. Any decline in tourist activity in the cities where these hotels are located could have a
negative effect on the use and occupancy of these hotels. As a consequence, this could have a
negative effect on the profitability and performance of these assets if tenants renegotiate current
leases.
Finally, it is important to bear in mind that there are other risks to which the Company is exposed: (i)
environmental risks; (ii) the risks associated with hygiene and health at work; and (iii) risks associated with
the prevention of occupational risks.